- Current report filing (8-K)
December 07 2012 - 4:53PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date Of Report (Date Of Earliest Event Reported):
December 7, 2012
NORTHWEST BIOTHERAPEUTICS, INC.
|
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware
|
|
000-33393
|
|
94-3306718
|
(State Or Other Jurisdiction Of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
4800 Montgomery Lane, Suite 800, Bethesda,
MD 20814
(Address Of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including
Area Code (240) 497-9024
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On December 7, 2012, Northwest Biotherapeutics,
Inc. (the “Company”) issued a press release announcing the pricing of its public offering of 3,000,000 shares of common
stock and warrants to purchase up to 1,500,000 shares of common stock, at an offering price of $4.00 per share of common stock
and $0.01 per warrant. The press release also announced the listing of the Company’s common stock and warrants on The NASDAQ
Capital Market under the symbols “NWBO” and “NWBOW,” respectively. A copy of the press release is attached
hereto as Exhibit 99.1.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
99.1
|
Press Release dated December 7, 2012
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
|
Dated: December 7, 2012
|
By:
|
/s/ Linda Powers
|
|
|
|
Name: Linda Powers
|
|
|
|
Title: Chief Executive Officer and Chairman
|
|
|
|
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jul 2023 to Jul 2024